News coverage about Ignyta (NASDAQ:RXDX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ignyta earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.0010397514838 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Ignyta (NASDAQ:RXDX) remained flat at $$26.95 on Friday. 254,655 shares of the stock were exchanged, compared to its average volume of 2,330,891. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.07 and a current ratio of 6.07. The company has a market cap of $1,821.52, a PE ratio of -9.98 and a beta of 1.92. Ignyta has a 1-year low of $5.80 and a 1-year high of $27.10.
Several brokerages recently weighed in on RXDX. Cantor Fitzgerald set a $15.00 target price on shares of Ignyta and gave the company a “buy” rating in a research note on Tuesday, October 17th. Jefferies Group downgraded shares of Ignyta from a “buy” rating to a “hold” rating and set a $27.00 target price for the company. in a research note on Thursday, December 28th. Zacks Investment Research downgraded shares of Ignyta from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. SunTrust Banks began coverage on shares of Ignyta in a research note on Monday, November 20th. They issued a “buy” rating for the company. Finally, Ladenburg Thalmann Financial Services boosted their target price on shares of Ignyta from $20.25 to $31.00 in a research note on Wednesday, October 18th. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Ignyta presently has a consensus rating of “Hold” and an average price target of $27.00.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.